John Nedelcu
Optometrist · Waterford, CTNPI 1457793432
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,335, 3.0 times the $440 reported in 2019. Among optometrist clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 107 payments — averaging $45.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$968
- Johnson & Johnson Vision Care, Inc.$918
- Bausch & Lomb Americas Inc.$688
- Sun Pharmaceutical Industries Inc.$409
- Tarsus Pharmaceuticals, Inc.$383
- Novartis$251
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,82498%
- Gifts$190%
- Entertainment$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 19 | $968 |
| Johnson & Johnson Vision Care, Inc. | 22 | $918 |
| Bausch & Lomb Americas Inc. | 17 | $688 |
| Sun Pharmaceutical Industries Inc. | 9 | $409 |
| Tarsus Pharmaceuticals, Inc. | 8 | $383 |
| Novartis | 3 | $251 |
| Rxsight Inc | 2 | $179 |
| Oyster Point Pharma, Inc. | 4 | $176 |
| AbbVie | 2 | $157 |
| Glaukos Corporation | 1 | $140 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Spark Therapeutics, Inc. | 1 | $125 |
| Dompe US, Inc. | 5 | $111 |
| Optos, Inc. | 3 | $60 |
| Biotissue Holdings Inc. | 2 | $51 |
| Coopervision Inc. | 2 | $51 |
| Kala Pharmaceuticals, Inc. | 2 | $40 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$397
- Precision7$273
- CEQUA$254
- XIIDRA$230
- XDEMVY$224
- iDose$140
- XELPROS$129
- ACTHAR$125
- VUITY$123
- VYZULTA$121
- MIEBO$115
- TRAVATAN Z$114
- DAILIES$100
- TYRVAYA$100
- RXSIGHT CONTACT LENS$100
- RXSIGHT INJECTOR CARTRIDGE$100
- RXSIGHT INJECTOR HANDPIECE$100
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$100
- LIGHT ADJUSTABLE LENS (LAL)$100
How this compares
$4,903 in reported general payments places this provider in the 90th percentile of 574 optometrist providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 45 | $51,104 |
| XiidraLifitegrast | 28 | $34,610 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $21,353 |
| LumiganBimatoprost | 24 | $19,124 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $14,141 |
| Cyclosporine | 25 | $13,783 |
| VyzultaLatanoprostene Bunod | 26 | $12,767 |
| TyrvayaVarenicline Tartrate | 17 | $11,303 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $10,883 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 62 | $7,721 |
| Travoprost | 59 | $6,028 |
| Loteprednol Etabonate | 15 | $2,834 |
| Latanoprost | 180 | $2,288 |
| Timolol Maleate | 52 | $210 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $157 | $91,581110 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $688 | $47,37654 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $16 | $14,14124 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $176 | $11,30317 claims |
| AlconSimbrinza | $968 | $10,88326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 574 optometrist providers in Connecticut.
Other optometrist in Waterford
- Joseph ThimonsFairfield$340K
- Inna LazarOld Greenwich$147K
- Jennifer StewartNew Canaan$91K
- Maria PribisStamford$78K
- Michael CooperWest Hartford$44K
- Joseph PavanoNew Britain$22K
- Susan JanikWest Hartford$20K
- Donald HigginsPlainville$18K
- Richard NowakEast Windsor$15K
- Barbara DuneHartford$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.